International Statistics and Epidemiology Group | LSHTM
Collaborating with international research partners to improve health in low and middle-income countries
๐ขFunded fellowships available๐ข
We have two fully funded medical statistics fellowships available for applicants from sub-Saharan Africa, covering
โถ๏ธ1 yr MSc in Medical Statistics at LSHTM
โถ๏ธ1 yr placement at a partnering research institution
๐๏ธClosing date 31st March
www.lshtm.ac.uk/research/cen...
03.02.2026 11:42 โ
๐ 1
๐ 1
๐ฌ 0
๐ 1
I'm currently jumping through hoops at one journal where the editors seem incapable of 'editing' and every single revision, no matter how minor, goes back out to the reviewers. 8 months in the system and counting...
18.12.2025 12:47 โ
๐ 2
๐ 0
๐ฌ 0
๐ 0
It's an excellent paper ๐
11.12.2025 14:06 โ
๐ 2
๐ 0
๐ฌ 0
๐ 0
I write my abstract in haiku.
05.12.2025 09:05 โ
๐ 0
๐ 0
๐ฌ 1
๐ 0
For this reason the combination of Xpert CT and a detailed CXR examination seems to be best at identifying those who may relapse post treatment.
30.09.2025 16:07 โ
๐ 2
๐ 0
๐ฌ 1
๐ 0
They may all represent seperate pathways, except smear and CT which intuitively may be related based on sputum. The great benefit of Xpert CT is the automatic readout with no need for reader interpretation. I imagine much of the variability in culture/smear comes from the operator.
30.09.2025 16:06 โ
๐ 1
๐ 0
๐ฌ 1
๐ 0
Correlations between CT, culture and CXR were weak, it's only smear that was reasonably correlated with CT. Smear and culture were weakly correlated with each other (R^2 14%), but neither correlated with CXR (both R^2 <10%).
30.09.2025 16:02 โ
๐ 1
๐ 0
๐ฌ 1
๐ 0
Hi Gabriele
Ultra is worse than Xpert at differentiating between the higher levels of disease severity. The study population was skewed towards a higher degree of disease severity, which may explain the lack of correlation between Ultra and CXR.
30.09.2025 15:55 โ
๐ 1
๐ 0
๐ฌ 1
๐ 0
Xpert MTB/RIFยฎ cycle threshold as a marker of TB disease severity; Implications for TB treatment stratification
โ
Just Accepted
#IDSky
๐ https://bit.ly/3WbLI1G
28.09.2025 19:17 โ
๐ 11
๐ 6
๐ฌ 1
๐ 5
Push to main.
25.09.2025 19:03 โ
๐ 0
๐ 0
๐ฌ 1
๐ 0
This paper has now been peer reviewed and is available open access at CID.
25.09.2025 18:38 โ
๐ 2
๐ 0
๐ฌ 0
๐ 0
The potential impact, cost and cost-effectiveness of tuberculosis interventions - a modelling exercise
Background While a range of interventions exist for tuberculosis prevention, screening, diagnosis, and treatment, their potential population impact and cost-effectiveness are seldom directly compared,...
At a time when global resources for #TB research, development, prevention, and care are limited, which interventions should be prioritised in high burden settings?
๐ข Our new pre-print compares the impact, cost, and cost-effectiveness of 9 TB interventions in 3 countries. 1/n
bit.ly/3V3vXth
05.09.2025 10:05 โ
๐ 11
๐ 9
๐ฌ 1
๐ 0
"Nobody suspects the dishwasher" sticks in memory from a previous round I attended somewhere.
03.09.2025 22:22 โ
๐ 1
๐ 0
๐ฌ 0
๐ 0
Academia may not give you job security, flexibility, or wealth, but it will let you unexpectedly connect to eduroam in foreign cities
20.08.2025 16:58 โ
๐ 1005
๐ 165
๐ฌ 30
๐ 21
Article on BBC news.
Title: AI designs antibiotics for gonorrhoea and MRSA superbugs
Description: Two new potential drugs have been designed by AI to kill drug-resistant bacteria, in a major Massachusetts Institute of Technology study.
I really dislike how science has started calling almost any fancy computational technique AI. ๐งช
The framing of this entire article makes it sound like a benevolent AI independently made these drugs.
That is *pure fantasy*.
Instead: a team of scientists made a machine learning model for a study.
15.08.2025 06:14 โ
๐ 2274
๐ 702
๐ฌ 57
๐ 55
p.s. I've been consistently spelling injectAble wrong for 3+ years now.
18.07.2025 15:12 โ
๐ 0
๐ 0
๐ฌ 0
๐ 0
The front page of the preprint article, showing title and authors
The abstract of the preprint
Forest plot showing primary and secondary trial outcomes, with non-inferiority margins
โก๏ธNew preprint (not peer-reviewed)โก๏ธ
In the SaDAPT trial with people with #HIV and #tuberculosis symptoms in ๐ฒ๐ผ๐ฑ๐ธ, we investigated if antiretroviral therapy should be initiated immediately, or delayed until TB results available. ssrn.com/abstract=523...
Outcomes (incl. IRIS) similar across both arms.
01.05.2025 07:10 โ
๐ 5
๐ 6
๐ฌ 1
๐ 0
Delighted to see our long-acting injectible ART trial (IMPALA) presented at #IAS2025. 2-monthly injections are non-inferior to daily pill taking and overwhelmingly preferred. Next challenge is expanding access to LA ART; excellent news the WHO has recommended LA CAB+RPV in treatment guidelines.
18.07.2025 15:03 โ
๐ 3
๐ 1
๐ฌ 1
๐ 0
Yeah, that part could definitely be better written. 10% mortality reduction is impressive!
18.07.2025 07:46 โ
๐ 0
๐ 0
๐ฌ 0
๐ 0
Interpretation beyond that is for the reader. It's possible these results could still change guidelines.
17.07.2025 10:25 โ
๐ 1
๐ 0
๐ฌ 1
๐ 0
I think you'd probably be right to, assuming there are no potential ill effects. 'Statistical significant' i.e. <0.05 is less of a thing now, but you still have to respect the study design. In this case, they just missed the pre-defined superiority criteria and must report on those lines.
17.07.2025 10:18 โ
๐ 1
๐ 0
๐ฌ 1
๐ 0
You don't need a Bayesian analysis to be less rigid in interpreting p- values. You're right the result looks promising, but it requires further study.
17.07.2025 09:52 โ
๐ 1
๐ 0
๐ฌ 1
๐ 0
Mandating culture/PCR for everyone in a vaccine trial makes sense to me, I didn't realise that wasn't the case. But it could (likely will) end up costing more even if the sample size is lower.
05.07.2025 13:36 โ
๐ 0
๐ 0
๐ฌ 0
๐ 0
Very interesting. In TB treatment trials, it's standard practice to test culture from everyone every few months regardless of symptoms. Consecutive positives define TB relapse without worrying about symptoms. However, this is a big cost driver!!!
05.07.2025 13:35 โ
๐ 1
๐ 0
๐ฌ 1
๐ 0
Describing the hawkeye automated line calling at Wimbledon as 'AI' can seriously get in the sea.
05.07.2025 11:46 โ
๐ 1
๐ 0
๐ฌ 0
๐ 0
add 10% to the quote you see when shopping around is my philosophy once it's been through the booking agent
26.06.2025 08:30 โ
๐ 0
๐ 0
๐ฌ 0
๐ 0
Until there is a test for TB infection with higher specificity than IGRA, the use of the non-inferiority trial design for TB vaccine prevention of infection outcomes is not recommended.
@richardwhite321.bsky.social @cfmcquaid.bsky.social @reinhouben.bsky.social
25.06.2025 20:22 โ
๐ 0
๐ 3
๐ฌ 0
๐ 0